Terms: = Pancreatic cancer AND CASP8, ALPS2B, 841, ENSG00000064012, MGC78473, CAP4, MACH, MCH5, FLICE AND Prognosis
14 results:
1. Establishment and external validation of prognosis prediction nomogram for patients with distant metastatic intrahepatic cholangiocarcinoma: based on a large population.
Yuan C; Zou S; Wang K; Hu Z
BMC Cancer; 2024 Feb; 24(1):227. PubMed ID: 38365630
[TBL] [Abstract] [Full Text] [Related]
2. MRI-Based Radiomics Nomogram for Preoperatively Differentiating Intrahepatic Mass-Forming Cholangiocarcinoma From Resectable Colorectal Liver Metastases.
Xu Y; Ye F; Li L; Yang Y; Ouyang J; Zhou Y; Wang S; Xie L; Zhou J; Zhao H; Zhao X
Acad Radiol; 2023 Sep; 30(9):2010-2020. PubMed ID: 37414635
[TBL] [Abstract] [Full Text] [Related]
3. machine learning-based model for prediction and feature analysis of recurrence in pancreatic neuroendocrine tumors G1/G2.
Murakami M; Fujimori N; Nakata K; Nakamura M; Hashimoto S; Kurahara H; Nishihara K; Abe T; Hashigo S; Kugiyama N; Ozawa E; Okamoto K; Ishida Y; Okano K; Takaki R; Shimamatsu Y; Ito T; Miki M; Oza N; Yamaguchi D; Yamamoto H; Takedomi H; Kawabe K; Akashi T; Miyahara K; Ohuchida J; Ogura Y; Nakashima Y; Ueki T; Ishigami K; Umakoshi H; Ueda K; Oono T; Ogawa Y
J Gastroenterol; 2023 Jun; 58(6):586-597. PubMed ID: 37099152
[TBL] [Abstract] [Full Text] [Related]
4. Dissection of pyroptosis-related prognostic signature and CASP6-mediated regulation in pancreatic adenocarcinoma: new sights to clinical decision-making.
Zhu J; Shi Y; Lan S; Wang J; Jiang F; Tang C; Cai Y; Pan Z; Jian H; Fang H; Zhang Y; Zhong F
Apoptosis; 2023 Jun; 28(5-6):769-782. PubMed ID: 36882663
[TBL] [Abstract] [Full Text] [Related]
5. CD44v6 expression in gastroenteropancreatic neuroendocrine neoplasms: Clinicopathological correlation and prognosis.
Nibhondhratana P; Watcharadetwittaya S; Sa-Ngiamwibool P
Pathol Res Pract; 2022 Dec; 240():154213. PubMed ID: 36403312
[TBL] [Abstract] [Full Text] [Related]
6. The relationships between antihypertensive medications and the overall survival of patients with pancreatic cancer: a systematic review and meta-analysis.
Jiang W; He R; Lu Y; Zhou W
Expert Rev Gastroenterol Hepatol; 2022 Jun; 16(6):547-553. PubMed ID: 35686669
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic Implications of an Autophagy-related Gene Signature in pancreatic Ductal Adenocarcinoma.
Liu WS; Feng YX; Li SN; Shao YJ; Wang K
Am J Clin Oncol; 2022 Mar; 45(3):95-104. PubMed ID: 35195559
[TBL] [Abstract] [Full Text] [Related]
8. Dietary intake of fatty acids and risk of pancreatic cancer: Golestan cohort study.
Ghamarzad Shishavan N; Masoudi S; Mohamadkhani A; Sepanlou SG; Sharafkhah M; Poustchi H; Mohamadnejad M; Hekmatdoost A; Pourshams A
Nutr J; 2021 Jul; 20(1):69. PubMed ID: 34271937
[TBL] [Abstract] [Full Text] [Related]
9.
Ye H; Li T; Wang H; Wu J; Yi C; Shi J; Wang P; Song C; Dai L; Jiang G; Huang Y; Yu Y; Li J
Front Immunol; 2021; 12():649551. PubMed ID: 33815409
[TBL] [Abstract] [Full Text] [Related]
10. Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans.
Sigel K; Zhou M; Park YA; Mutetwa T; Nadkarni G; Yeh C; Polak P; Sigel C; Conroy T; Juzyna B; Ychou M; Fojo T; Wisnivesky JP; Bates SE
Semin Oncol; 2021 Feb; 48(1):69-75. PubMed ID: 33714591
[TBL] [Abstract] [Full Text] [Related]
11. LncRNA DLX6-AS1 as a potential molecular biomarker in the clinicopathology and prognosis of various cancers: a meta-analysis.
Tian S; Liu J; Kong S; Peng L
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32785606
[TBL] [Abstract] [Full Text] [Related]
12. Relationship between SDC1 and cadherin signalling activation in cancer.
Liao S; Liu C; Zhu G; Wang K; Yang Y; Wang C
Pathol Res Pract; 2020 Jan; 216(1):152756. PubMed ID: 31810587
[TBL] [Abstract] [Full Text] [Related]
13. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
[TBL] [Abstract] [Full Text] [Related]
14. Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.
Weberpals J; Jansen L; van Herk-Sukel MPP; Kuiper JG; Aarts MJ; Vissers PAJ; Brenner H
Eur J Epidemiol; 2017 Nov; 32(11):1019-1031. PubMed ID: 28864947
[TBL] [Abstract] [Full Text] [Related]
